Allied Market Research recently published a report, titled, “Antifibrinolytic Drugs Market by Indication (Gynecology, Hereditary Angiedema, Fibrinolytic Response Testing, Surgeries, and Others) and End user (Hospitals & Clinics, Ambulatory Surgical Centers, and Healthcare Specialty Process): Global Opportunity Analysis and Industry Forecast, 2019–2026″. According to the report, the global antifibrinolytic drugs industry was pegged at $13.59 billion in 2018 and is projected to reach $19.33 billion by 2026, registering a CAGR of 4.5% from 2019 to 2026.
Access Sample Data & Findings:
https://www.alliedmarketresearch.com/request-sample/6279
North America region held the lion’s share
The global antifibrinolytic drugs market across North America held the largest share in 2018, contributing to more than two-fifths of the market, owing to surge in surgeries in the region. However, the market across the Asia-Pacific region is expected to register the fastest 6.1% during the forecast period, owing to increase in road accidents in this region.
By type, the gynaecology segment accounted for majority of the market share in 2018 and is expected to exhibit a prominent growth rate in the near future, owing to the increased adoption of these drugs to prevent menorrhagia i.e. heavy menstrual flow. Further, these drugs are manufactured to reduce bleeding by inhibiting endometrial clot-dissolving enzymes in the uterine lining. Tranexamic acid (TXA) is the most widely used drug for controlling menorrhagia.
By end user, the hospitals & clinics segment dominated the antifibrinolytic drugs market in 2018 and is anticipated to maintain its dominance during the forecast period. This is attributed to the increased usage of these drugs in hospitals as most of the surgeries such as cardiovascular and neurosurgeries are performed in hospitals.
Chief reasons for market fluctuations
Rise in severe road accidents and significant increase in surgical procedures have boosted the growth of the global antifibrinolytic drugs market. However, high cost of these drugs hampers the market growth. On the contrary, untapped potential in developing countries is expected to create lucrative opportunities in the near future.
★ See What’s Inside This Report @
https://www.alliedmarketresearch.com/purchase-enquiry/6279
Major Key Players –
- Xanodyne Pharmaceuticals
- ACIC Fine Chems
- Aurobindo Pharma Ltd.
- Amerigen Pharms Ltd
- Akorn
- Pfizer (GenMed)
- Mylan
- Zydus Cadila
- Sanofi
- Takeda
The gynecology segment dominated the market
The gynecology segment held the largest share in 2018, contributing to nearly one-third of the global antifibrinolytic drugs market, owing to increased adoption of these drugs to prevent menorrhagia i.e. heavy menstrual flow. However, the surgeries segment is expected to manifest the fastest CAGR of 5.9% during the study period, owing to significant increase in the number of surgeries being performed across the globe.
The trauma centers segment to manifest the fastest growth
The trauma center segment is anticipated to portray the fastest CAGR of 5.1% during the forecast period, owing to remarkable increase in road accidents globally. However, the hospitals and clinics segment held the largest share in 2018, accounting for nearly half of the global antifibrinolytic drugs market share. This is due to increased usage of these drugs in hospitals as most of the surgeries such as cardiovascular and neurosurgeries are performed in hospitals.
Simply Speak To Analyst In A Single Click:
https://www.alliedmarketresearch.com/connect-to-analyst/6279
About Us
Allied Market Research (AMR) is a full-service market research and business consulting wing of Allied Analytics LLP based in Wilmington, Delaware. Allied Market Research provides end-to-end solutions along with information, education, advocacy, and networking resources to SMEs and early-stage start-ups to bring excellence to their processes. In addition, we offer a nurturing environment required to develop and grow businesses, including business planning; virtual support; market intelligence; acquiring resources; and getting direct access to finance, suppliers, and other experts to boost the growth of businesses and entrepreneurs.
Our bundled and hassle-free business support systems are customized to meet the needs of SME consultants and industry leaders. Moreover, our large network of skilled consultants and experts help start-ups get the business on a roll.
Contact:
David Correa
1209 Orange Street,
Corporation Trust Center,
Wilmington, New Castle,
Delaware 19801 USA.
Toll Free: +1-800-792-5285
Int’l: +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
[email protected]
